

Datasheet for ABIN1408061
anti-EPS15 antibody (AA 161-260) (Cy5.5)



[Go to Product page](#)

Overview

Quantity:	100 µL
Target:	EPS15
Binding Specificity:	AA 161-260
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This EPS15 antibody is conjugated to Cy5.5
Application:	Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunofluorescence (Cultured Cells) (IF (cc))

Product Details

Immunogen:	KLH conjugated synthetic peptide derived from human EPS15
Isotype:	IgG
Predicted Reactivity:	Human,Mouse,Rat,Pig
Purification:	Purified by Protein A.

Target Details

Target:	EPS15
Alternative Name:	EPS15 (EPS15 Products)
Background:	Synonyms: AF 1P, AF 1p protein, AF1P, ALL1 fused gene from chromosome 1, Epidermal

Target Details

growth factor receptor pathway substrate 15, Epidermal growth factor receptor substrate 15, EPS 15, MLLT 5, MLLT5, Protein Eps 15, Protein Eps15, EPS15_HUMAN.

Background: Elucidation of the mechanism by which receptor tyrosine kinases (RTKs) modulate cellular physiology in response to stimuli is critical to the understanding of growth regulation. Miscues in RTK signaling pathways can result in cellular transformation and ultimately in cancer. Two novel EGF receptor substrates designated EGF-receptor pathway substrates 8 and 15, or Eps8 and Eps15, have been described. Eps8 and Eps15 are proteins, respectively that become tyrosine phosphorylated subsequent to EGF stimulation.

Overexpression of Eps15 in NIH/3T3 cells causes cellular transformation, implying involvement in the regulation of cell proliferation. Eps15 is capable of binding the amino terminal portion of Crk via a conserved proline-rich domain, characteristic of all Crk binding proteins (5).

Overexpression of Eps8 in both fibroblasts and hematopoietic cells results in an increased mitogenic response to EGF. Eps8 has been shown to associate with the EGF receptor despite its lack of a functional SH2 domain. Further characterization suggests the protein has both a PH domain and a SH3 domain, the functional significance of which are not yet known.

Pathways: [EGFR Signaling Pathway](#), [Regulation of Muscle Cell Differentiation](#), [Skeletal Muscle Fiber Development](#), [EGFR Downregulation](#)

Application Details

Application Notes: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 µg/µL

Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling

Storage:	-20 °C
Storage Comment:	Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Expiry Date:	12 months